To study the effect of pioglitazone (PIO) on plasma resistin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) in patients with type II diabetes (T2DM). SUBJECTS: A total of 13 T2DM patients (age ¼ 5172 y, BMI ¼ 29.771.1 kg/m 2 , HbA 1c ¼ 8.070.5%). METHODS: HFC (magnetic resonance spectroscopy) and basal plasma resistin concentration were quantitated before and after PIO treatment (45 mg/day) for 16 weeks. Subjects received a 3 h euglycemic insulin (100 mU/m 2 /min) clamp with 3-[ 3 H] glucose to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO. RESULTS: PIO reduced fasting plasma glucose (10.370.7 to 7.670.6 mmol/l, Po0.001) and HbA 1c (8.070.4 to 6.870.3%, Po0.001) despite increased body weight (83.273.4 to 86.373.4 kg, Po0.001). PIO improved Rd (4.970.4 to 6.670.5 mg/ kg/min, Po0.005) and reduced EGP (0.2270.04 to 0.0670.02 mg/kg/min, Po0.01) during the insulin clamp. Following PIO, HFC decreased from 21.173.5 to 11.272.1% (Po0.005), and plasma resistin decreased from 5.370.6 to 3.570.3 ng/ml (Po0.01). Plasma resistin concentration correlated positively with HFC before (r ¼ 0.58, Po0.05) and after (r ¼ 0.55, Po0.05) PIO treatment. Taken collectively, plasma resistin concentration, before and after PIO treatment, correlated positively with hepatic fat content (r ¼ 0.66, Po0.001) and EGP during the insulin clamp (r ¼ 0.41, Po0.05). However, the plasma resistin concentration did not correlate with whole body glucose disposal (Rd) during the insulin clamp either before (r ¼ À0.18, P ¼ NS) or after (r ¼ À0.13, P ¼ NS) PIO treatment. CONCLUSIONS: PIO treatment in T2DM causes a significant decrease in plasma resistin concentration. The decrease in plasma resistin is positively correlated with the decrease in hepatic fat content and improvement in hepatic insulin sensitivity.
Introduction
The adipocyte functions not only as a storage depot for fat but also as an endocrine organ that releases hormones in response to specific extracellular stimuli or changes in metabolic status. These secreted proteins, which include tumor necrosis factor (TNF)-a, leptin, adipsin, resistin, adiponectin, and others, carry out a variety of diverse functions, [1] [2] [3] and collectively have been referred to as 'adipokines'. These adipokines have been postulated to play important roles in the pathogenesis of insulin resistance, glucose intolerance, inflammation, and atherosclerosis. [1] [2] [3] Resistin is a member of the newly discovered cysteine-rich secretory protein family, referred to as 'resistin-like molecules' (RELM) or 'found in inflammatory zone' (FIZZ). Resistin is FIZZ3 and, together with FIZZ1/RELM a and FIZZ2/RELM b, comprise the FIZZ family of proteins. 4 Each of these proteins has unique tissue distribution, and both resistin and FIZZ1/RELM a are expressed in adipose tissue. Initial studies 5 in rodents suggested that resistin is upregulated in obesity and was involved in the development of insulin resistance. Serum resistin levels were shown to be elevated in obese mice and immunoneutralization of circulating resistin improved insulin sensitivity and glucose tolerance. 5 Moreover, treatment of normal mice with recombinant resistin led to an impairment glucose tolerance and insulin action. Resistin expression was also shown to be decreased by treatment of a murine adipocyte cell line with rosiglitazone, a peroxisome proliferator-activated gamma (PPAR-g) receptor agonist. Rosiglitazone also reduced the elevated serum resistin concentration in mice. However, subsequent studies demonstrated reduced resistin expression in adipose tissue of obese animals, 6 and from obese humans. 7 Moreover, the investigators 7 were unable to demonstrate any relationship between adipocyte resistin mRNA levels and severity of obesity. To the best of our knowledge, the effect of thiazolidinediones on circulating plasma resistin concentrations in type II diabetics has not been examined. This is of significant importance since Rajala et al 8 have demonstrated that the infusion of either resistin or RELM b induces severe hepatic, but not peripheral, insulin resistance in rodents.
The role of resistin in the etiology of obesity, insulin resistance, and type II diabetes (T2DM) in humans remains debatable. While some studies have reported that resistin expression is almost undetectable in human adipose tissue, 7, 9 other studies have demonstrated that resistin expression is increased in abdominal compared to thigh fat depots in obese humans. 10 Furthermore, while insulin inhibits resistin gene expression in 3T3-L1 adipocytes, 11 it stimulates resistin protein secretion, without altering gene expression, from human abdominal adipocytes in vitro, suggesting that increased resistin secretion may be an important link between visceral obesity, insulin resistance, hyperinsulinemia, and increased risk for T2DM. 12 In a recent study, adipose tissue resistin expression in obese nondiabetic humans was shown to be related to hepatic fat content and insulin resistance as determined by the HOMA model. 13 These observations are of considerable interest since studies from our laboratory 14 and others [15] [16] [17] [18] have provided evidence that increased hepatic fat content is an important determinant of hepatic insulin resistance in type II diabetic patients, and fatty liver is common in type II diabetic patients. 19, 20 Although thiazolidinediones have been shown to reduce hepatic fat content and improve hepatic insulin sensitivity in patients with T2DM, 14 no previous study has examined whether the decrease in hepatic fat content and/or the improvement in hepatic insulin sensitivity is (are) related to the thiazolidinedione-mediated decrease in plasma resistin concentration in type II diabetic patients. Therefore, the current study was undertaken to examine the effect of pioglitazone (PIO) treatment on plasma resistin levels and its relationship to hepatic fat content and both hepatic and peripheral (muscle) tissue sensitivity to insulin in type II diabetic patients. ]-glucose to quantitate whole body glucose disposal (Rd) and endogenous (primarily hepatic) glucose production (EGP). All studies were performed at 08:00 h following a 10-12 h overnight fast. Sulfonylurea-treated subjects discontinued their medication 48 h prior to the euglycemic insulin clamp study. Sulfonylureas have been shown to have no direct effects on tissue sensitivity to insulin. 22 Following completion of these studies, subjects were started on PIO, 45 mg/day, for 16 weeks. During the PIO treatment period, subjects returned to the Clinical Research Center every 2 weeks at 08:00 h, following an overnight fast, for measurement of fasting plasma glucose concentration, body weight, and blood pressure. Fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol) were measured monthly. HbA 1c was measured twice during the last week of PIO treatment. On each visit, dietary adherence was reinforced. After 16 weeks of PIO treatment, all subjects underwent a repeat measurement of (i) fasting plasma glucose, free fatty acids, resistin, and insulin concentration; (ii) hepatic fat content; and (iii) insulin sensitivity.
Methods

Subjects
Euglycemic insulin clamp
Subjects were admitted to the GCRC at 18:00 h on the evening before the study and a standard, weight-maintain- /min) was initiated to reduce and maintain the plasma glucose concentration to B100 mg/dl (5.55 mmol/l).
At 08:00 h on the following day, a second catheter was inserted retrogradely into a vein on the dorsum of the hand for blood sampling and the hand was placed in a heated box (601C) for the duration of the study. A euglycemic insulin (100 mU/m 2 /min) clamp was begun and continued for 3 h. During the 180 min of the euglycemic insulin clamp, a primed (25 mCi)-continuous (0.25 mCi/min) infusion of 3-[ 3 H]-glucose (started with the onset of insulin infusion) was given via the antecubital vein to measure endogenous glucose production. Arterialized blood samples were collected every 5 min for plasma glucose determination and a 20% glucose infusion was adjusted to maintain the plasma glucose concentration at B100 mg/dl (5.55 mmol/l). 21 Blood samples for determination of plasma insulin concentration were obtained every 15-30 min throughout the study. Plasma samples for the determination of 3-[ 3 H]-glucose specific activity were obtained every 5-10 min during the 150-180 min period of the euglycemic insulin clamp. During the 150-180 min time period of the insulin clamp, the exogenous glucose infusion rate required to maintain euglycemia was constant.
Liver fat content (proton magnetic resonance spectroscopy) Localized 1 H NMR spectra of the liver were acquired on a 1.9 T MRI scanner (Elscint Prestige Ltd, Elscint, Haifa, Israel), using a standard body coil in transmitter and receiver mode. An initial T1-weighted spin-echo anatomical MR scan for liver MRS localization was performed with the following parameters: repetition time (TR)/echo time (TE)/y ¼ 130 ms/15 ms/1601; slice thickness ¼ 7 mm; field of view ¼ 44 cm Â 45 cm; number of excitations ¼ 1; and an image matrix ¼ 100 Â 256. The slice with the largest gross dimensions of the liver was chosen for the MRS study. MRS for water and fat quantification was accomplished using a point resolved spectroscopy sequence (PRESS). 23 The imaging parameters for PRESS sequence were as follows: TR/TE/y ¼ 1500 ms/54 ms/901; number of averages ¼ 2; and data points ¼ 512. A 3 cm Â 3 cm Â 3 cm volume (voxel) was selected in the left, right anterior, and right posterior hepatic lobes for scanning to provide a generalized distribution of fat within the liver. During the measurements, the subject lay supine within the bore of the magnet. The total scan time was approximately 60 min. During the MRS examinations, identical areas of the liver were scanned in the pre and posttreatment MRS studies of the same subject by the use of anatomical landmarks visualizing images.
After line broadening, phase and baseline correction, the peak area of the water (Sw) at 4.77 ppm and fat resonance (Sf) at 1.4 ppm were measured. Quantification of the fat content was carried out by comparing the area of the fat resonance with that of the unsuppressed water. Spectroscopic data was processed using the Elscint operating system software. Hepatic fat percentage was calculated by dividing (100 Â Sf) by the sum of Sf and Sw. This technique is highly reproducible, with a CV less than 2% when the same subjects were studied on eight separate days.
Analytical determinations
Plasma glucose concentration was measured by the glucose oxidase method (Beckman Instruments, Fullerton, CA, USA). Plasma insulin concentration was measured by radioimmunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA). Tritiated glucose specific activity was determined on deproteinized barium/zinc plasma samples as previously described. 24 Plasma-free fatty acid concentration was determined by an enzymatic colorimetric quantification method (Wako Chemicals, Nuess, Germany). Plasma resistin concentration was measured by ELISA (United States Biological, Swampscott, MA, USA). The resistin standards used in the assay were 4.0 and 12.5 ng/ml. The sensitivity of the assay was 0.2 ng/ml, and the interassay coefficient of variation was 6%.
Calculations
During the euglycemic insulin clamp, the rate of total body glucose appearance (Ra) was calculated using Steele's equation 25 and a distribution volume of 250 ml/kg. EGP was calculated by subtracting the exogenous glucose infusion rate from the tracer-derived measure of Ra. The rate of insulin-mediated Rd was determined by adding the rate of residual EGP to the exogenous glucose infusion rate.
Statistical analysis
Statistical calculations were performed with StatView for Windows, version 5.0 (SAS Institute, Cary, NC, USA). Values before and after treatment were compared using paired t-test. Linear or logarithmic (for nonlinearly distributed data) regression analysis was used to examine the relationships between hepatic insulin sensitivity, hepatic fat content, and the plasma resistin concentration. Statistical significance of the relationship was determined using the ANOVA regression table. Data are presented as mean7s.e.m. A P-value o0.05 was considered to be statistically significant.
Results
Metabolic parameters ( Glucose metabolism during the insulin clamp Following PIO treatment, the insulin-stimulated rate of whole body glucose disposal rate (Rd) was significantly increased (6.670.5 vs 4.970.4 mg/kg/min, Po0.005), and the suppression of endogenous glucose production during the euglycemic insulin clamp was significantly enhanced (0.0670.02 vs 0.2270.04 mg/kg/min, Po0.01).
Hepatic fat content PIO therapy resulted in a significant decrease (Figure 1 
Discussion
The present study represents the first comprehensive attempt in man to examine the relationship between the plasma resistin concentration, hepatic/peripheral insulin sensitivity, and body weight and hepatic fat content in type II diabetic subjects before and after treatment with a Resistin, hepatic fat content and hepatic insulin resistance M Bajaj et al
thiazolidinedione. Our results demonstrate that PIO treatment significantly reduces circulating plasma resistin concentration by 34%, and that the decrease in plasma resistin concentration is closely related to the decrease in hepatic fat content and the improvement in hepatic insulin sensitivity.
To the best of our knowledge, present investigation represents the first study to demonstrate a relationship between plasma resistin levels and hepatic insulin sensitivity and hepatic fat content in patients with T2DM. Further, we show for the first time that the decrease in plasma resistin concentration following PIO treatment is associated with improvements in both hepatic fat content (decreased) and hepatic insulin sensitivity (increased). Of note, plasma resistin levels did not correlate with peripheral (muscle) insulin sensitivity, BMI, or fasting plasma insulin, FFA, triglyceride, HDL, or LDL cholesterol concentrations. Some insight into the mechanisms via which resistin influences glucose production by the liver has been provided by in vivo studies in animals. 8 Injection of recombinant resistin in rats in the presence of hyperinsulinemia enhanced flux through glucose-6-phosphatase and increased rates of gluconeogenesis, glycogenolysis, and glucose cycling. These results clearly demonstrate that a pharmacologic increase in plasma resistin concentration can induce hepatic insulin resistance in animals in vivo and are consistent with the strong correlation observed between the plasma resistin concentration and hepatic insulin resistance observed in type II diabetic subjects in the present study. The biochemical/molecular mechanism(s) via which resistin causes hepatic insulin resistance remains to be defined. Thiazolidinediones initiate their metabolic effects by binding to and activating the PPARg. 26 PPARg activation causes apoptosis of large fat cells in intra-abdominal fat depots and the differentiation of preadipocytes into mature fat cells in subcutaneous fat depots, along with the induction of key enzymes involved in lipogenesis. 27, 28 14, 30 and peripheral insulin sensitivity.
14, [29] [30] [31] Thiazolidinediones also have been shown to inhibit the expression of resistin in cultured 3T3-L1 adipocytes 11, 32 and in white adipose tissue of db/db mice. 33 Thus, inhibition of resistin secretion by visceral adipocytes in response to thiazolidinedione treatment may play a role in the hepatic insulin-sensitizing effects of this class of drugs. Although we did not investigate the expression of resistin in adipose tissue in the present study, one could speculate that the decrease in resistin levels and the associated decrease in hepatic fat content, as well as the improvement in hepatic insulin sensitivity following PIO treatment are secondary to decreased transcription of the resistin gene in visceral adipocytes. 11, 32 However, since resistin is also produced by mononuclear cells, 34 an inhibitory effect of PIO on resistin secretion by these cells cannot be excluded. We believe that the contamination of the resistin assay by mononuclear blood cells (which should be random) is an unlikely explanation for the systemic decline in plasma resistin concentration that was observed in the present study.
Resistin has been shown to inhibit the differentiation of preadipocytes into mature fat cells. 35 Therefore, a PIOmediated inhibition of resistin expression 11,32 could contribute to the differentiation of preadipocytes into mature fat cells in subcutaneous fat depots and explain the welldocumented effect of thiazolidinediones to increase subcutaneous fat mass. 29, 31 It is noteworthy that the plasma resistin concentration in type II diabetics did not correlate with peripheral insulin resistance in the present study. This observation is consistent with animal studies which failed to demonstrate any effect of pharmacologic increases in the plasma resistin concentration on peripheral (muscle) insulin sensitivity. 8 Although PIO treatment was associated with a 35% increase in peripheral (muscle) insulin sensitivity and a decline in resistin concentrations, we failed to observe any relationship between the decrease in plasma resistin and the improvement in peripheral insulin sensitivity. Consistent with this observation, plasma resistin concentrations did not correlate with plasma FFA levels before and after PIO treatment. We also failed to observe any relationship between plasma resistin levels and the laboratory manifestations of insulin resistance (metabolic) syndrome, 2 that is increased fasting plasma triglyceride, insulin, and glucose concentrations and decreased HDL cholesterol concentration. In summary, the present results demonstrate that PIO treatment significantly decreases the plasma resistin concentration in patients with T2DM. The decrease in plasma resistin levels is associated with a decrease in hepatic fat content and an improvement in hepatic insulin sensitivity. The decrease in plasma resistin concentration following Figure 2 The relationship between hepatic fat content and plasma resistin concentration before (K) and after (J) PIO treatment in type II diabetic patients.
Resistin, hepatic fat content and hepatic insulin resistance M Bajaj et al thiazolidinedione therapy may play an important role in reversing the impairment in hepatic fat and glucose metabolism in type II diabetic patients.
